Get the Stockscreener App
74.96
2.66%
1.94
After Hours:
74.95
-0.010
-0.01%
Dexcom Inc stock is traded at $74.96, with a volume of 3.83M.
It is up +2.66% in the last 24 hours and up +0.25% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$73.02
Open:
$73.33
24h Volume:
3.83M
Relative Volume:
0.68
Market Cap:
$28.93B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
32.06
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+5.21%
1M Performance:
+0.25%
6M Performance:
+11.22%
1Y Performance:
-12.29%
1-Day Range:
$73.31
$75.57
1-Week Range:
$69.74
$75.57
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.96 | 28.93B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's why you should retain DexCom stock in your portfolio - MSN
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom to release Q2 2026 earnings on July 30, 2026 - scanx.trade
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured - Yahoo Finance
Press Release: Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 P.m. Eastern Time - Moomoo
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
Dexcom Inc. focuses on continuous glucose monitoring as investors track long-term growth - AD HOC NEWS
Dexcom Inc. focuses on continuous glucose monitoring growth. Long-term diabetes trends support the b - Ad-hoc-news.de
Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems? - simplywall.st
Dexcom (DXCM) Executive Chair sells 26,756 shares in 10b5-1 open-market trade - Stock Titan
Dexcom Inc. updates its diabetes tech platform as investors track long-term growth - AD HOC NEWS
Devon Energy Corp focuses on U.S. shale production as investors track cash returns - AD HOC NEWS
DexCom (NASDAQ: DXCM) Form 144 lists proposed sale of 26,756 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Barchart.com
DXCMDexcom Inc Latest SEC Filings - Finviz
Earnings Preview: What To Expect From DexCom's Report - Yahoo Finance
Dexcom G7 Continuous Glucose Monitor from Dexcom Inc.smaller sensor and direct-to-watch in the US - AD HOC NEWS
JPMorgan (NYSE: JPM) offers autocall contingent-interest notes tied to DexCom stock - Stock Titan
DexCom shareholders urged to act as law firm pr... - Pluang
Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM) - Yahoo Finance
Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM) – - The National Law Review
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Inc (DXCM) Stock Up 3.5% and Still Undervalued -- GF Scor - GuruFocus
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's (DXCM) Investment Narrative? - Sahm
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Price to earnings forward of DexCom, Inc. – SIX:DXCM - TradingView
Enterprise value to EBIT forward of DexCom, Inc. – SIX:DXCM - TradingView
Devon Energy expands Permian drilling plan, shares tied to oil price swings - AD HOC NEWS
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover - The National Law Review
DexCom, Inc. (DXCM) Investor Outlook: Seizing a 21.53% Upside in the Booming CGM Market - DirectorsTalk Interviews
Dexcom Inc. extends Stelo reach, shares in focus on NASDAQ - AD HOC NEWS
Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky Before December 26, 2025 to Join Class Action - The National Law Review
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):